EMA reports ‘critical deficiencies’ in Chinese API producer Jinan Jinda

Home/Pharma News | Posted 02/09/2016 post-comment0 Post your comment

A recent European Medicines Agency’s (EMA) follow up on Jinan Jinda Pharmaceutical Chemi Co Ltd (Jinan Jinda) revealed that the Chinese pharmaceutical company is far off meeting EU standards.

58 MD002163

The action began in June 2015 when EU regulators clamped down on the active pharmaceutical ingredient (API) producer for inferior manufacturing. Problems were discovered following an inspection of their plant in Zhangqiu, Shandong, which produces nitrofurantoin, an antibiotic commonly used to treat bladder infections.

The inspection revealed 18 deficits and concluded that there was a serious risk of data being falsified, leading the European Directorate for the Quality of Medicines (EDQM) to suspend its certificate of suitability for nitrofurantoin.

Soon after, Jinan Jinda brought in US consultant ChemWerth – a generic API development and supply specialist – to fix the problems and help the company return to the European market. However, a recent follow up by the Spanish Agency of Medicines and Medical Devices found that the company was still shipping the antibiotic to some European customers, despite not meeting the standards required by the EU.

The check-up, a year on from the initial inspection, showed that the list of problems at the plant had grown from 18 to 30. Eight of these were classified as major (including problems in training, quality assessment and cleaning) and two as critical (including how the plant handles raw data).

The Spanish investigators acting on behalf of EMA reported that the company had not implemented corrective and preventive actions in a satisfactory manner, and was still not in compliance with Good Manufacturing Practice (GMP).
As such, the EDQM recommended that the antibiotic produced by Jinan Jinda be banned from the EU and that the plant’s certificate of compliance be suspended or perhaps even voided. The full statement can be found on the EMA’s database for manufacturers authorizations and GMP certificates, EudraGMDP.

Related articles
EMA halts sales of unreliable generics

China introduces new quality and efficacy requirements for generics

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: EMA

comment icon Comments (0)
Post your comment
Related content
GaBI news digest for 14 October 2022
56 AA011042
Home/Pharma News Posted 14/10/2022
Novartis is set to spin-off Sandoz
Guidance V13F21
Home/Pharma News Posted 16/09/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010